Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorder (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorder (NMOSD). This report contains market size and forecasts of Neuromyelitis Optica Spectrum Disorder (NMOSD) in global, including the following market information:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Intravenous Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics and TG Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Type, 2022 (%)
Intravenous
Oral
Subcutaneous
Others
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuromyelitis Optica Spectrum Disorder (NMOSD), market overview.
Chapter 2: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size in revenue.
Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuromyelitis Optica Spectrum Disorder (NMOSD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Overall Market Size
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2022 VS 2029
2.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
3.2 Top Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Ranked by Revenue
3.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies
3.4 Top 3 and Top 5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
3.6.1 List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Markets, 2022 & 2029
4.1.2 Intravenous
4.1.3 Oral
4.1.4 Subcutaneous
4.1.5 Others
4.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
4.2.1 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2023
4.2.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2024-2029
4.2.3 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
5.2.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2023
5.2.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2024-2029
5.2.3 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2022 & 2029
6.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
6.2.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2023
6.2.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2024-2029
6.2.3 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029
6.3.2 US Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029
6.4.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.4 U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.5 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.6 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.7 Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.4.8 Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029
6.5.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.5.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.5.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.5.5 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.5.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029
6.6.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.6.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029
6.7.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.7.3 Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.7.4 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
6.7.5 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2018-2029
7 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Profiles
7.1 F. Hoffmann-La Roche Ltd
7.1.1 F. Hoffmann-La Roche Ltd Company Summary
7.1.2 F. Hoffmann-La Roche Ltd Business Overview
7.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.1.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.2 Alexion Pharmaceuticals
7.2.1 Alexion Pharmaceuticals Company Summary
7.2.2 Alexion Pharmaceuticals Business Overview
7.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.2.5 Alexion Pharmaceuticals Key News & Latest Developments
7.3 RemeGen
7.3.1 RemeGen Company Summary
7.3.2 RemeGen Business Overview
7.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.3.5 RemeGen Key News & Latest Developments
7.4 Nihon Pharmaceutical
7.4.1 Nihon Pharmaceutical Company Summary
7.4.2 Nihon Pharmaceutical Business Overview
7.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.4.5 Nihon Pharmaceutical Key News & Latest Developments
7.5 Harbour BioMed
7.5.1 Harbour BioMed Company Summary
7.5.2 Harbour BioMed Business Overview
7.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.5.5 Harbour BioMed Key News & Latest Developments
7.6 Lundbeck
7.6.1 Lundbeck Company Summary
7.6.2 Lundbeck Business Overview
7.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.6.5 Lundbeck Key News & Latest Developments
7.7 Bionure
7.7.1 Bionure Company Summary
7.7.2 Bionure Business Overview
7.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.7.5 Bionure Key News & Latest Developments
7.8 Opexa Therapeutics
7.8.1 Opexa Therapeutics Company Summary
7.8.2 Opexa Therapeutics Business Overview
7.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.8.5 Opexa Therapeutics Key News & Latest Developments
7.9 TG Therapeutics
7.9.1 TG Therapeutics Company Summary
7.9.2 TG Therapeutics Business Overview
7.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.9.5 TG Therapeutics Key News & Latest Developments
7.10 Bio-Thera Solutions
7.10.1 Bio-Thera Solutions Company Summary
7.10.2 Bio-Thera Solutions Business Overview
7.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.10.5 Bio-Thera Solutions Key News & Latest Developments
7.11 Boston Pharmaceuticals
7.11.1 Boston Pharmaceuticals Company Summary
7.11.2 Boston Pharmaceuticals Business Overview
7.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.11.5 Boston Pharmaceuticals Key News & Latest Developments
7.12 Cour Pharmaceutical
7.12.1 Cour Pharmaceutical Company Summary
7.12.2 Cour Pharmaceutical Business Overview
7.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2018-2023)
7.12.5 Cour Pharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunities & Trends in Global Market
Table 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers in Global Market
Table 3. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints in Global Market
Table 4. Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Global Market
Table 5. Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Companies, 2018-2023
Table 8. Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
Table 9. List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2024-2029
Table 30. F. Hoffmann-La Roche Ltd Company Summary
Table 31. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 32. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 33. F. Hoffmann-La Roche Ltd Key News & Latest Developments
Table 34. Alexion Pharmaceuticals Company Summary
Table 35. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 36. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 37. Alexion Pharmaceuticals Key News & Latest Developments
Table 38. RemeGen Company Summary
Table 39. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 40. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 41. RemeGen Key News & Latest Developments
Table 42. Nihon Pharmaceutical Company Summary
Table 43. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 44. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 45. Nihon Pharmaceutical Key News & Latest Developments
Table 46. Harbour BioMed Company Summary
Table 47. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 48. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 49. Harbour BioMed Key News & Latest Developments
Table 50. Lundbeck Company Summary
Table 51. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 52. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 53. Lundbeck Key News & Latest Developments
Table 54. Bionure Company Summary
Table 55. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 56. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 57. Bionure Key News & Latest Developments
Table 58. Opexa Therapeutics Company Summary
Table 59. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 60. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 61. Opexa Therapeutics Key News & Latest Developments
Table 62. TG Therapeutics Company Summary
Table 63. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 64. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 65. TG Therapeutics Key News & Latest Developments
Table 66. Bio-Thera Solutions Company Summary
Table 67. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 68. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 69. Bio-Thera Solutions Key News & Latest Developments
Table 70. Boston Pharmaceuticals Company Summary
Table 71. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 72. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 73. Boston Pharmaceuticals Key News & Latest Developments
Table 74. Cour Pharmaceutical Company Summary
Table 75. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
Table 76. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn) & (2018-2023)
Table 77. Cour Pharmaceutical Key News & Latest Developments
List of Figures
Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Type in 2022
Figure 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Application in 2022
Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2022
Figure 8. By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 9. By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 10. By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 12. By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 14. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 15. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 16. US Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 20. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 21. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 28. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 32. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 34. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2018-2029
Figure 37. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2018-2029
Figure 41. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
